Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prestige Consumer Healthcare (PBH) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Prestige Consumer Healthcare (PBH) over the last 17 years, with Q4 2025 value amounting to -$57.0 million.

  • Prestige Consumer Healthcare's Net Cash Flow fell 414290.78% to -$57.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $10.3 million, marking a year-over-year increase of 18988.11%. This contributed to the annual value of $52.0 million for FY2025, which is 52613.11% up from last year.
  • According to the latest figures from Q4 2025, Prestige Consumer Healthcare's Net Cash Flow is -$57.0 million, which was down 414290.78% from -$20.4 million recorded in Q3 2025.
  • Over the past 5 years, Prestige Consumer Healthcare's Net Cash Flow peaked at $131.6 million during Q2 2021, and registered a low of -$119.9 million during Q3 2021.
  • In the last 5 years, Prestige Consumer Healthcare's Net Cash Flow had a median value of $1.8 million in 2023 and averaged $89700.0.
  • Per our database at Business Quant, Prestige Consumer Healthcare's Net Cash Flow surged by 43959.91% in 2021 and then tumbled by 414290.78% in 2025.
  • Over the past 5 years, Prestige Consumer Healthcare's Net Cash Flow (Quarter) stood at -$21.6 million in 2021, then soared by 299.9% to $43.1 million in 2022, then crashed by 95.05% to $2.1 million in 2023, then plummeted by 33.9% to $1.4 million in 2024, then tumbled by 4142.91% to -$57.0 million in 2025.
  • Its Net Cash Flow stands at -$57.0 million for Q4 2025, versus -$20.4 million for Q3 2025 and $40.8 million for Q2 2025.